Microbot Medical Expands Access to Veteran and Military Markets Through Lovell Government Services Agreement
Key Highlights
- Microbot Medical Inc. (NASDAQ: MBOT) has entered a significant agreement with Lovell Government Services, a Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor, to expand access for the LIBERTY® Endovascular Robotic System across over 2,000 U.S. government healthcare facilities.
- The agreement opens up new sales channels for Microbot Medical’s flagship LIBERTY® System throughout the U.S. Department of Veterans Affairs (VHA), Department of Defense’s Military Health System (MHS), and the Indian Health Service (IHS).
- Lovell Government Services will manage federal contracting and procurement for Microbot, streamlining government sales and helping agencies meet SDVOSB procurement goals.
- The LIBERTY® System will be listed on Lovell’s Federal Supply Schedule (FSS) contract, with activation expected in Q3 2026, and will be accessible through other major federal procurement platforms such as GSA Advantage, Defense Logistics Agency’s ECAT, and the Department of Defense’s DAPA.
- The company is targeting federal healthcare providers with an average of over 200 peripheral endovascular cases annually per site, signaling high usage potential for the LIBERTY® system.
Details and Strategic Implications for Investors
Microbot Medical’s latest agreement marks a significant commercial development for the company. As a commercial-stage medical device firm focused on advanced robotic technology for endovascular procedures, Microbot’s expansion into the federal healthcare market provides access to a large, stable customer base, potentially leading to material revenue growth.
Through its partnership with Lovell Government Services, a four-time Inc. 5000 honoree with a proven record since 2013, Microbot leverages Lovell’s expertise and network to introduce its LIBERTY® Endovascular Robotic System to a broad range of U.S. government healthcare facilities. This includes 170 medical centers and numerous outpatient clinics, collectively performing a substantial number of vascular procedures annually.
The LIBERTY® System is a single-use, remotely operated endovascular robotic device, designed to improve precision, efficiency, and safety in minimally invasive vascular interventions. The availability of the system through multiple established federal procurement platforms ensures streamlined purchasing for government clients and supports agencies in meeting procurement requirements for SDVOSB suppliers.
According to Chris Lovell, CEO of Lovell Government Services and retired Major, USMC, the partnership aims to connect government healthcare providers with best-in-class technologies to improve patient outcomes and simplify procurement. Christina Bailey, Vice President of U.S. Sales at Microbot, emphasized that contracted access through Lovell is a key component of the company’s commercial strategy, providing a streamlined pathway to customers and bolstering product availability.
The company expects that this agreement will not only expand awareness and adoption of the LIBERTY® System across Lovell’s network but also accelerate commercial momentum and potentially drive broader adoption throughout the federal healthcare landscape.
Potential Shareholder Impact and Price-Sensitive Elements
- Access to Federal Markets: The agreement grants Microbot Medical entry to a vast federal healthcare market, historically known for stable, recurring procurement contracts.
- Revenue Growth Potential: If the LIBERTY® System achieves significant adoption across VHA, MHS, and IHS facilities, it could result in substantial revenue growth and market share expansion for Microbot.
- SDVOSB Procurement Goals: Government agencies are incentivized to purchase from SDVOSB vendors, potentially increasing sales velocity for Microbot’s products via Lovell.
- Federal Supply Schedule Activation Timeline: With FSS activation expected in Q3 2026, investors should watch for updates on procurement volumes and initial orders, which may serve as early indicators of financial impact.
- Regulatory and Market Risks: The company notes risks related to commercialization, regulatory approvals, geopolitical factors, and maintenance of intellectual property.
Bottom Line for Investors: This agreement represents a potentially significant commercial catalyst for Microbot Medical, with the possibility to materially impact future revenues and market positioning. Shareholders should monitor progress on the FSS activation and initial procurement activity, as these developments could drive share price movement.
About Microbot Medical
Microbot Medical Inc. develops and commercializes robotic medical devices for endovascular procedures. Its flagship product, the LIBERTY® Endovascular Robotic System, is designed to improve procedural outcomes and patient safety, and the company is backed by a strong intellectual property portfolio.
For more information, visit www.microbotmedical.com
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Forward-looking statements involve risks and uncertainties, including market conditions, regulatory matters, and other factors, and actual results may differ materially. Investors should review all company filings and consult with a financial advisor before making investment decisions.
